Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progesterone receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    265 result(s) found for: Progesterone receptor. Displaying page 3 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-001552-36 Sponsor Protocol Number: 18SEIN08 Start Date*: 2020-09-09
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-α status in patients with metastatic breast cancer HER2 + and ERα neg treated with trastuzumab + pertuz...
    Medical condition: Metastatic breast cancer HER2 + and ERα neg.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002918-41 Sponsor Protocol Number: IJB-EBC-Decrescendo-2020 Start Date*: 2021-08-25
    Sponsor Name:Institut Jules Bordet
    Full Title: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chem...
    Medical condition: HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001795-53 Sponsor Protocol Number: CLEE011G2301 Start Date*: 2017-11-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone r...
    Medical condition: Hormone receptor-positive, Estrogen and/or progesterone receptor-positive, HER2-negative, High risk early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020819 10006203 Breast cancer stage unspecified LLT
    20.0 100000115074 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011299-32 Sponsor Protocol Number: 20060359 Start Date*: 2010-08-06
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence
    Medical condition: Early-stage non-metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) HU (Completed) GB (Completed) ES (Prematurely Ended) CZ (Completed) LV (Completed) FR (Completed) BE (Completed) SK (Completed) NL (Completed) IE (Prematurely Ended) DK (Completed) SI (Completed) GR (Completed) IT (Completed) BG (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001548-36 Sponsor Protocol Number: CO40016 Start Date*: 2017-12-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATI...
    Medical condition: Locally advanced unresectable or metastatic triple-negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer or locally advanced unresectable or metastatic hormone recept...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BE (Completed) FR (Completed) GR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002178-23 Sponsor Protocol Number: CA180-088 Start Date*: 2006-12-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific...
    Medical condition: Women with recurrent or progressive locally-advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000810-12 Sponsor Protocol Number: CO41101 Start Date*: 2019-12-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META...
    Medical condition: Metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022902-41 Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g Start Date*: 2011-09-26
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa...
    Medical condition: Patients with operable HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) FR (Completed) IE (Completed) SE (Completed) DK (Completed) SI (Completed) NL (Completed) BE (Completed) SK (Completed) AT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005954-22 Sponsor Protocol Number: VEG108843 Start Date*: 2008-06-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus p...
    Medical condition: Advanced or metastatic hormone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020835-38 Sponsor Protocol Number: IEOS550310 Start Date*: 2011-09-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: “A phase II study of cisplatin plus cyclophospamide for patients with previously treated, advanced, triple receptor negative breast cancer”
    Medical condition: Advanced, triple receptor negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002596-40 Sponsor Protocol Number: A35148 Start Date*: 2007-03-22
    Sponsor Name:World Health Organization
    Full Title: Comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination: a randomized, placebo-controlled, multicentre trial
    Medical condition: Termination of early pregnancy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003327-39 Sponsor Protocol Number: KKSH-14 Start Date*: 2006-04-21
    Sponsor Name:Martin-Luther-University
    Full Title: Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II...
    Medical condition: oligometastatic breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000558-71 Sponsor Protocol Number: 9090-11 Start Date*: 2012-07-25
    Sponsor Name:Synta Pharmaceuticals Corp.
    Full Title: An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women with Breast Cancer
    Medical condition: HER2 positive, triple negative breast cancer (TNBC) and hormone-receptor (ER/PR)-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    16.1 10022891 - Investigations 10054057 Progesterone receptor assay positive PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002588-24 Sponsor Protocol Number: CLEE011A2201 Start Date*: 2013-12-30
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer
    Medical condition: HR+, HER2- early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005742-14 Sponsor Protocol Number: GS-US-592-6173 Start Date*: 2022-08-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced I...
    Medical condition: Programmed cell death ligand 1 (PD-L1) positive metastatic triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003084-61 Sponsor Protocol Number: CLEE011A2301 Start Date*: 2014-01-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast ...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) NL (Completed) HU (Completed) FI (Completed) IE (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000179-29 Sponsor Protocol Number: CMCS110Z2201 Start Date*: 2015-04-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC)
    Medical condition: Advanced Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020819 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) FR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005127-29 Sponsor Protocol Number: TAX_GMA_302 Start Date*: 2001-05-21
    Sponsor Name:SANOFI-AVENTIS
    Full Title: MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTI...
    Medical condition: node positive and high risk node negative patients with operable breast cancer containing the the HER2 alteration.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001488-60 Sponsor Protocol Number: WSG-AM11 Start Date*: 2020-07-09
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus stand...
    Medical condition: HR+/HER2- early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002334-23 Sponsor Protocol Number: 2017-03 Start Date*: 2017-09-29
    Sponsor Name:Dutch Breast Cancer Research Group (BOOG)
    Full Title: Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trial
    Medical condition: hormone receptor positive advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 11:13:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA